Botulinum Toxin Evaluated in Digital Ischemia
Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies
By
Kathryn Wighton
April 3, 2026
Clinical Scorecard: Botulinum Toxin Evaluated in Digital Ischemia
At a Glance
Category Detail
Condition Digital ischemia, ischemic digital ulcers, gangrene Key Mechanisms Botulinum toxin injections improve blood flow and tissue recovery Target Population Patients with digital ischemia, particularly those with autoimmune conditions Care Setting Outpatient or clinical settings where botulinum toxin can be administered
Key Highlights
93% complete response in acute digital ischemia 90% complete response in ischemic ulcers 88% complete response in gangrene Most patients required a single injection session Adverse events were uncommon, primarily transient muscle weakness and injection site pain Guideline-Based Recommendations
Diagnosis
Evaluate for underlying conditions such as systemic sclerosis and other rheumatic diseases Management
Administer botulinum toxin injections to interdigital neurovascular bundles at doses of 5 to 10 units per digit side Monitoring & Follow-up
Assess for response to treatment and monitor for adverse events Risks
Transient muscle weakness (8%) and injection site pain (6%) Patient & Prescribing Data
Primarily female patients with a mean age of 49 years, often with systemic sclerosis
Higher doses of botulinum toxin are associated with higher complete response rates
Clinical Best Practices
Consider botulinum toxin for patients unresponsive to vasodilators Monitor response rates in autoimmune-related ischemia Utilize multiple formulations of botulinum toxin as needed Related Resources & Content
